ocrelizumab
ocrelizumab is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including OCREVUS. Available dosage forms: liquid, injection.
Drug Details
- Generic Name
- ocrelizumab
- Brand Names
- OCREVUS
- Application Number
- BLA761053
- Sponsor
- Lonza Biologics, Inc.
- NDC Codes
- 4
- Dosage Forms
- LIQUID, INJECTION
- Routes
- INTRAVENOUS
- Active Ingredients
- OCRELIZUMAB
Indications and Usage
1 INDICATIONS AND USAGE OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more. OCREVUS is a CD20-directed cytolytic antibody indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 ) Primary progressive MS, in adults ( 1 ) Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more ( 1 )